GlassScriptPhysician profile
Robert L Ruxin
NPI 1316042104
$10,286.39
in general payments reported to CMS, 2019-2025
39 companies · $1,003 in 2025
The $1,003 reported for 2025 was more than what 85% of Internal Medicine providers received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $2,433 · 2020: $954 · 2021: $1,499 · 2022: $1,791 · 2023: $1,414 · 2024: $1,192 · 2025: $1,003.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,602 · Education: $6.65.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,602.02 |
| Education | $6.65 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Lilly USA, LLC | $1,726.71 | 2019-2025 | Jardiance, Mounjaro, Zepbound |
| Astrazeneca Pharmaceuticals LP | $1,249.96 | 2019-2025 | Breztri, Farxiga |
| Sanofi-Aventis U.S. LLC | $1,164.68 | 2019-2023 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $1,086.47 | 2019-2025 | Jardiance |
| Amgen INC. | $826.71 | 2019-2025 | Evenity, Tepezza, Prolia |
| Novo Nordisk INC | $630.49 | 2019-2024 | Wegovy, Ozempic |
| Abbott Laboratories | $619.96 | 2020-2025 | Freestyle Libre 3 |
| Merck Sharp & Dohme LLC | $367.73 | 2019-2021 | |
| Esperion Therapeutics, INC. | $345.72 | 2021-2024 | Nexletol |
| Bayer Healthcare Pharmaceuticals INC. | $321.99 | 2021-2022 | |
| Medtronic Minimed, INC. | $294.05 | 2019-2020 | |
| Medtronic, INC. | $232.65 | 2021-2025 | Minimed 780g |
| Janssen Pharmaceuticals, INC | $144.18 | 2019-2021 | |
| Currax Pharmaceuticals LLC | $143.24 | 2019-2024 | Contrave |
| Cequr Corporation | $121.54 | 2022-2025 | Cequr Simplicity |
Show all 39 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Corcept Therapeutics | $103.67 | 2019-2024 | Korlym |
| Novartis Pharmaceuticals Corporation | $100.86 | 2019 | |
| Exact Sciences Corporation | $74.29 | 2025 | The Cologuard Plus Collection Kit |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $65.49 | 2022-2023 | Xifaxan |
| Amneal Pharmaceuticals LLC | $65.42 | 2022-2024 | Unithroid |
| Radius Health, INC. | $62.86 | 2024 | Tymlos |
| Glaxosmithkline, LLC. | $54.38 | 2022-2024 | Arexvy, Shingrix |
| Csl Behring | $52.38 | 2025 | Andembry |
| Biocryst US Sales Co., LLC | $51.79 | 2021 | |
| Abbvie INC. | $47.50 | 2019-2025 | |
| Pfizer INC. | $37.70 | 2024-2025 | |
| Therapeuticsmd, INC. | $34.17 | 2019 | |
| Biocryst Pharmaceuticals, INC. | $32.73 | 2020 | |
| Amarin Pharma, INC. | $24.92 | 2019 | |
| Intra-Sana Laboratories | $24.18 | 2025 | Reltone 400 Mg, Reltone 200 Mg, Glycate |
| Allergan, INC. | $23.86 | 2019 | |
| E.R. Squibb & Sons, L.L.C. | $23.70 | 2024 | Eliquis |
| Insulet Corporation | $22.81 | 2025 | Omnipod |
| Shield Therapeutics INC | $20.79 | 2025 | |
| Dexcom, INC. | $19.10 | 2023 | Dexcom G6 Transmitter |
| Halozyme INC | $19.08 | 2023 | |
| Xeris Pharmaceuticals, INC. | $19.07 | 2025 | Gvoke Hypopen |
| Nalpropion Pharmaceuticals LLC | $16.10 | 2019 | |
| Janssen Biotech, INC. | $13.46 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Robert Ruxin listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.